One year follow-up of the cardio-metabolic profile evolution in renal transplant patients treated with alemtuzumab, cyclosporine, and steroids in a reference hospital in Colombia

• Published in: Iatreia (Medellín, Colombia) Colombia), 2015-10, Vol.28 (4), p.388-399
• Main Authors: Nieto-Ríos, JF, Gómez-Rueda, NV, Serna-Higuita, LM, Ocampo-Kohn, C, Aristizábal-Alzate, A, Abadía-Guzmán, H, Yepes-Delgado, CE, Zuluaga-Valencia, G
• Format: Article
• Language: eng ; spa
• Subjects: Cardiovascular Disease; Cardiovascular Risk Factors; MEDICINE, GENERAL & INTERNAL; Renal Transplantation
• ISSN: 0121-0793; 2011-7965
• DOI: 10.17533/udea.iatreia.v28n4a04

Introduction: Cardiovascular events occur 50 times more often in kidney transplant patients than in the general population and are the leading cause of death. The aim of the study was to evaluate the behavior of cardio-metabolic profile and determine the incidence of major cardiovascular events in the first year after transplantation. Methods: This prospective study evaluated the behavior of cardio-metabolic profile in adult patients that were transplanted during 2011. Results: The median age was 44.3 ± 12.05 years, 68.7 % were men and 95.5 %, hypertensive. Alemtuzumab-cyclosporine and steroids were used in 89.6 %, delaying the introduction of the antimetabolite. In the first year after transplantation there were three cases of diabetes mellitus, three major cardiovascular events, and 12 cases of acute rejection. Albumin, hemoglobin, weight, body mass index (BMI), calcium and HbA1C increased (p